The Medical Innovation Agenda for the 119th Congress

The Future of Medical Innovation: The 119th Congress Agenda
The 119th Congress has a historic opportunity to champion policies that will revolutionize patient care—accelerating access to groundbreaking medical tests, treatments, and technologies that save and improve lives. The Medical Innovation Agenda outlines the most pressing priorities shaping the future of healthcare, from driving advancements in medical technology to ensuring equitable access for all patients.
By downloading this exclusive Medical Innovation Agenda, you’ll gain insider insights into the key policy initiatives that will define the next era of healthcare innovation. Be part of the movement advocating for progress—fill out the form now to access your copy and stay ahead of the latest developments in medtech policy!
Related Reading
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why Lifesaving Medtech Should Be Tariff-free: An Interview with AdvaMed’s CEO
April 30, 2025
AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential, lifesaving medtech products.
News / China / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
April 25, 2025
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech.
News / Diagnostics / Radiation Therapy
Carbon Medical Technologies’ BiomarC Tissue Marker Line Achieves EU MDR Certification
April 25, 2025
April 25, 2025 – Carbon Medical Technologies, Inc. (CMT), a manufacturer of pyrolytic carbon-coated medical devices used in biopsy procedures, for radiation therapy, and to treat stress urinary incontinence, is proud to announce that our BiomarC Tissue Marker System has successfully achieved certification under the European Union Medical Device Regulation (EU MDR 2017/745).
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why the Administration Should Be Flexible with Medtech Tariffs to Protect Patients and Innovation
April 25, 2025
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain
Tariffs: Understanding the Nairobi Protocol and related Customs Procedures
Now On Demand
Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs. Join us April 30, 2–3:30pm ET.
News / Diagnostics / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Releases “AI Policy Roadmap” to Guide Congress and Federal Agencies
April 22, 2025
Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the next era of artificial intelligence-enabled medical and digital health technologies to provide patients and clinicians transformative new tools to aid in diagnosis and treatment.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Tariffs Should Spare Vital U.S. MedTech Industry
April 17, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
News / Diagnostics / Digital Health
Satio, Nanowear announce partnership offering first, holistic, home-based in vivo- + in vitro diagnostics + drug delivery
April 15, 2025
BOSTON and NEW YORK, April 14, 2025 /PRNewswire/ — Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home blood draw diagnostics and drug delivery systems/patches: combining time synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk assessment.